A study by HECON Associates, a Maryland-based market research group, supports the claim that when prescription drugs become available over the counter, consumers face increased out-of-pocket costs.
The study focused on four drugs that recently became available over the counter. Researchers compared OTC costs with what consumers would pay in a mixed managed care/ indemnity plan (such as a private PPO), a typical HMO, and Maryland's Medicaid program. Sharp increases in out-of-pocket expenses were seen when products went to OTC status, due to the lack of an OTC drug benefit: As much as 113 percent in the managed care/indemnity plan, 233 percent in the HMO, and 9,000 percent for the Medicaid group, whose average pharmacy copayment was 13 cents.

Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.